Astra to study ticagrelor in PAD patients

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
AstraZeneca is launching the EUCLID study, an international clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America. EUCLID is designed to evaluate cardiovascular (CV) event rates and safety in PAD patients.

Ticagrelor (Brilinta) is currently not approved for the treatment of patients with PAD.

EUCLID is a randomized, double-blind, parallel group, multicenter study evaluating the efficacy of ticagrelor (monotherapy) compared with clopidogrel (monotherapy) in reducing the primary endpoint—a composite of CV death, MI or ischemic stroke—in patients with PAD.

In the EUCLID study, symptomatic PAD patients who are 50 years of age or older will be randomized to receive either ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily. Now that plans to initiate the study have been finalized, the EUCLID steering committee will begin recruiting study investigators, clinical centers, and eventually patients.

William R. Hiatt, MD, a professor of medicine in the division of cardiology at the University of Colorado School of Medicine in Denver, is the principal investigator for the EUCLID study. It is being conducted in partnership with the Duke Clinical Research Institute, an academic research organization affiliated with the Duke University School of Medicine, and CPC Clinical Research, an academic research organization affiliate of the University of Colorado.

The EUCLID study (Examining Use of tiCagreLor In paD) is part of the PARTHENON program, an AstraZeneca-funded, long-term research initiative seeking to address unanswered questions in atherothrombotic disease, and to investigate the impact of ticagrelor on CV events and death. The current PARTHENON program is designed to include more than 51,000 patients worldwide.

The first clinical study of PARTHENON was PLATO (A Study of PLATelet Inhibition and Patient Outcomes).